. Kenyataan Di FB oleh Kementerian Kesihatan Msia (11.06.2020 @ 4.30pm)
Negara Brazil mencatatkan kenaikan jumlah kes harian melebihi 4 kali ganda iaitu 65,004 kes berbanding semalam iaitu 15,654 kes dan menjadikan negara ini mempunyai bilangan kes harian yang tertinggi di dunia.
Negara dari Amerika Latin ini juga menduduki tangga kedua selapas negara Amerika Syarikat bagi jumlah kes COVID-19 seluruh negara di dunia.
Kes kesembuhan dunia hampir kepada 47%, negara Malaysia berada di kedudukan ke-52 bagi kes yang sembuh.
@puki, you said that "dont use hard earn money to gamble, I advice people to do proper inverstment and dont gamble. The share price has told everything"..............i want you to come up with calculations to support your statement, simple as that....i can go to every counter and say A-Z also like your hobby in Rubberex. ..
all i can say is, what goes around, comes around.....your karma will follow you..your own intention is known by you, within you...btw, today most gloves closed (including Topglove) red if you didnt know that , and if you also didn't know, Topglove profit is 350 mil, , achieved 200%..
Wow Comfort Gloves justed posted impressive latest QR. Net Profit jumped 94% to almost RM17 Million. Also rewarded shareholders with 1.5 interim dividend.
Friend, you can never make everyone happy. A jump of 94 % in Net Profit is certainly a very impressive result. Of course we expect the next quarter result will be better with higher ASP and more demand. Not many company listed at Bursa Malaysia at this moment can posted such a sterling performance. I also wish that Ruberex can match or exceed Comfort Glove result. Let us wait and see. Regards.
It's funny that when the QR results are out, people start to act like wise guru and judge the share price & financials as if they previously bought the share based on its financials instead of market sentiment. It's never about the financials. It's all about market sentiment.
Pharma companies announce plans to advance trials Moderna, a Cambridge, Massachusetts-based biotech company, said Friday that it plans to start its phase III trial in July. The trial, the last step needed to determine whether a vaccine is effective at preventing coronavirus, will include 30,000 volunteers.
@onionchong , ..everyone is entitle to their own opinion..its not about being a guru, its about using those fundamentals to do valuation from financial ratios..results from qr are the key components to derive the fair value and forward calculations..market sentiments is another story, dont mix these two things up.
onion, if you are new or not familiar, please follow big 4 glove forums as there are good analysts that come up with constructive methods of valuation.
7@8 years ago hartalega also from small cap about 500millions..not strong supporters but as we can see nowadays?we see the bright future for this company due to high demand actually ruberex start to growth from 2018 based on fundamentally..the company went to europe in 2018 to promoted their product..we arent buy for suka2
Comfort is good but i prefer ruberex because the company looks likely more generous might be they can give better divident than comfort and fastest growth in the future..just my 2 cents
ROME (Reuters) - British drugmaker AstraZeneca Plc said on Saturday it signed a contract with Italy, Germany, France and the Netherlands to supply Europe with a vaccine against the coronavirus, with deliveries starting by the end of 2020.
The contract is for up to 400 million doses of the vaccine, developed by the University of Oxford, the company said, adding that it was looking to expand manufacturing of the vaccine, which it pledged to provide for no profit during the pandemic.
“With our European supply chain due to begin production. The experimentation phase of the vaccine is already advanced and expected to end in the autumn, Italian Health Minister Roberto Speranza said in a Facebook post.
AstraZeneca has agreed manufacturing deals globally to meet its target of producing 2 billion doses of the vaccine, including with two ventures backed by Bill Gates and a $1.2 billion agreement with the U.S. government.
There are no approved vaccines or treatments for COVID-19, the highly contagious respiratory illness caused by the novel coronavirus.
“Many countries in the world have already secured vaccines, Europe has not yet. The rapid coordinated action of a group of member states will create added value for all EU citizens in this crisis,” German Health Minister Jens Spahn said.
The European Commission received a mandate from EU governments on Friday to negotiate advance purchases of promising coronavirus vaccines, the EU’s top health official said, but it was unclear whether there would be enough money available.
Reporting by Giuseppe Fonte in ROME, Rama Venkat in BANGALORE, additional reporting by Madeline Chambers in BERLIN, writing by Giulia Segreti; editing by John Stonestreet and Louise Heavens
☝Analysts have been giving Top Glove higher target prices. Do you see the valuations of gloves being supported by real demand? Will gloves and healthcare sector continue to lead the market?
Given that gloves are the clear beneficiaries of the Covid-19 pandemic, we do see that there is a significant pent-up demand in the near and medium term. While a vaccine has yet to be found, glove manufacturers will enjoy a supercycle period of bumper profits in view of lower raw material prices, monthly or quarterly increases in selling prices, weaker ringgit and expected capacity increases. This has yet to take into account any potential supply disruptions between the United States and China if trade tensions worsened. This would further drive up demand. The recent spikes in glove stocks are capturing the impact of higher selling prices, where a simple 10% increase in average selling prices can effectively double their net profits. Beyond the Covid-19 pandemic, we believe that the annual demand growth trajectory in medical gloves will be significantly higher than before the pandemic as developed countries will keep higher levels of stock, while developing countries will see a hike in glove usage. This would be in line with experiences from previous pandemics that the companies have operated through. Therefore, current prices also aim to capture the longer term dynamics post-Covid-19.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
EagleEye
499 posts
Posted by EagleEye > 2020-06-11 19:45 | Report Abuse
.
Kenyataan Di FB oleh Kementerian Kesihatan Msia (11.06.2020 @ 4.30pm)
Negara Brazil mencatatkan kenaikan jumlah kes harian melebihi 4 kali ganda iaitu 65,004 kes berbanding semalam iaitu 15,654 kes dan menjadikan negara ini mempunyai bilangan kes harian yang tertinggi di dunia.
Negara dari Amerika Latin ini juga menduduki tangga kedua selapas negara Amerika Syarikat bagi jumlah kes COVID-19 seluruh negara di dunia.
Kes kesembuhan dunia hampir kepada 47%, negara Malaysia berada di kedudukan ke-52 bagi kes yang sembuh.
#PrayForBrazil